TEVA logoTEVA
Teva- Pharmaceutical Industries Ltd. - ADR

26,938
Loading...
Loading...
News
all
press releases
Can Galafold Drive Amicus' Growth Through the Rest of 2025?
Galafold's steady growth, rising sales and strong patent protection position Amicus for continued growth and momentum through 2025.
Zacks·7d ago
News Placeholder
More News
News Placeholder
Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks·9d ago
News Placeholder
Here's How Alvotech is Expanding its Portfolio Beyond Immunology
ALVO accelerates growth with soaring revenues and new biosimilars in ophthalmology, oncology and neurology via global alliances.
Zacks·9d ago
News Placeholder
Alvotech vs. Teva Pharma: Which Generic Drugmaker is the Better Play?
ALVO's partnership-driven model fuels surging biosimilar revenues, while TEVA leans on scale but faces debt and competitive pressures.
Zacks·16d ago
News Placeholder
J&J Adds $63B in Market Cap in 3 Months: Time to Buy the Stock?
J&J shares gain 17.7% in three months, adding $63B to its market cap. Technical and pipeline momentum fuel investor interest.
Zacks·17d ago
News Placeholder
Here's How ALVO's Commercial Partnerships Are Driving Top-line Growth
Alvotech's partnership-led strategy drives soaring biosimilar revenues, fresh approvals and a diversified pipeline across key therapies.
Zacks·21d ago
News Placeholder
ALVO Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell?
Alvotech trades near a 52-week low after a 38% drop in 2025, but soaring revenues and new biosimilar approvals highlight its growth path.
Zacks·30d ago
News Placeholder
TEVA Stock Up More Than 19% in a Month: Buy, Sell or Hold the Stock?
Teva expects 2025 generics growth to be flat to low single digit, with U.S. trends and the Japan divestment influencing results.
Zacks·1mo ago
News Placeholder
This Pharma Stock Is Down 19% In 2025 But Just Received An ‘Explosive News’ – Find Out More
The company’s U.S. affiliate announced that the U.S. Food and Drug Administration has approved a generic version of Liraglutide injection, known as Saxenda.
Stocktwits·1mo ago
News Placeholder
J&J Stock Trading Above 200 & 50 Day SMA for 2 Months: Time to Buy?
Johnson & Johnson stock surges above key moving averages as strong results, raised guidance and growth prospects fuel momentum.
Zacks·1mo ago

Latest TEVA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.